publication date: Dec. 18, 2010

In this issue: 

NCI Director Halts STELLAR Trial, Seeks “Brilliant Ideas” For Breast Cancer Prevention.

Decision To Stop NSABP P-4 Study Before It Starts Shocks Clinical Trialists.

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

Download (PDF 816KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.